熱門資訊> 正文
Arcitis表示Zoryve数据表明特应性皮炎可持续改善
2025-06-06 21:34
- New phase 3 data released by Arcutis Biotherapeutics (NASDAQ:ARQT) on Zoryve (roflumilast) found that the cream leads to durable improvement in of atopic dermatitis symptoms over the long term.
- Results from the open-label INTEGUMENT-OLE study found that in children 2-5 years old who saw disease clearance and then switched to proactive twice-weekly application Zoryve, the median duration of disease control was 238 days.
- For adults down to children age 6, the figure was 281 days.
- The new data will be presented at the 2025 Revolutionizing Atopic Dermatitis Conference.
More on Arcutis Biotherapeutics
- Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside
- Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript
- Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets
- Arcutis wins FDA nod for Zoryve foam for plaque psoriasis
- Arcutis outlines growth potential with ZORYVE expansions and market penetration
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
